• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Fluoroquinolone
    1 Drug classified under this drug class


    All the Drug Class Drugs

    Ciprodex 500
    Dexcel
    RX
    partial basket chart
    Ciprodex 500

    Fluoroquinolone. Ciprofloxacin (as hydrochloride) 500 mg.
    CAPS: 10 x 500mg. Upper & lower respirat. tract infec.: 500-750mg ×2/d for 7-14 d.
    Malig. extern. otitis: 750 mg ×2/d for 28 d.  up to 3 mnths.
    Uncomplic. cystitis: 250-500mg ×2/d for 3 d. (in pre-menopaus. women, 500 mg single dose may be used).
    Complic. cystitis, Uncomplic. pyelonephritis: 500 mg ×2/d for 7 d.
    Complic. pyelonephritis: 500-750 mg ×2/d for at least 10 d.
    Prostatitis: 500-750 mg ×2/d for at least 14 d.
    Gonococcal urethritis & cervicitis: 500mg as a single dose.
    Epididymo-orchitis & pelvic inflamm. dis.: 500-750mg ×2/d for at least 14 d.
    Diarrhoea caused by bact. pathogens includ. Shigella spp. other than Shigella dysenteriae type 1 and empirical tmt. of severe travellers' diarrhea: 500mg twice dly. for 1 d.
    Diarrhoea caused by Shigella dysenteriae type 1: 500mg ×2/d for 5 d.
    Diarrhoea caused by Vibrio cholera:
    500mg
    ×2/d for 3 d.
    Typhoid fever: 500mg ×2/d for 7 d.
    Intra-abdom. infec. due to Gram-neg. bact.: 500-750mg ×2/d for 5-14 d.
    Infec. of the skin & soft tissue: 500-750mg ×2/d for 7-14 d.
    Bone & joint infec.: 500-750mg ×2/d for max. of 3 mnths.
    Neutropenic pts. with fever suspected to be due to a bact. infec.
    Ciprofloxacin should be co-admin. with appropriate antibact. agent(s) in accord. to official guidance: 500-750mg ×2/d over the entire period of neutrop.
    Prophylaxis of invas. infec. due to Neisseria meningitidis: 500 mg as a single dose.
    Inhalat. anthrax post-exposure prophylax., curative tmt. for persons able to receive tmt. by oral route when clinic. appropriate. Drug admin. should begin as soon as possible after susp. or confir. exposure: 500mg ×2/d for 60 d. from the confirm.of Bacillus anthracis exposure.
    See lit.
    Ped.population: CF:  20 mg/kg bdy. wt. ×2/d with a max. of 750 mg  per dose for 10-14 days.
    Complic. UTI's & pyelonephritis: 10 mg/kg bdy. wt. ×2/d to 20 mg/kg bdy. wt. ×2/d with a max. of 750 mg/dose for 10-21 d. Inhal. anthrax post-exposure prophylax. & curative tmt. for persons able to receive tmt. by oral route when clinic. appropriate. Drug admin. should begin as soon as possible after susp. or confirm. exposure: 10 mg/kg bdy. wt.×2/d to 15 mg/kg bdy. wt.×2/d with a max. of 500 mg per dose for 60 d. from the confirm. of Bacillus anthracis exposure.
    Other severe infec.: 20 mg/kg bdy. wt. ×2/d with a max. of 750 mg/dose (durat. of tmt. accord. to the type of infec.). See lit.
    Adult.: Broad spect. antibiot. for infec. caused by ciprofloxacin sensit. pathogens.
    Child.& adolesc.: Broncho -pulmon. infec. in CF caused by Pseudomonas aeruginosa.
    Complic. UTI's &pyelonephritis.
    Inhal. anthrax (post-exposure prophylax. & curative tmt.).
    Ciprofloxacin may also be used to treat severe infec. in child. & adolesc. when there is no other alternative.
    Tmt. should be initiated only by physicians who are experienc. in the tmt.  of CF and/or severe infec. in child. & adolesc. See lit.
    C/I: Hypersens. to the active subst., to other quinolones. Concom. admin. with tizanidine. See lit.

    CLOSE